Unaudited Financial results for the quarter ended 30.06.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vista Pharmaceuticals reported unaudited Q1 FY26 results with revenue from operations of Rs. 151.88 lakhs, down from Rs. 179.50 lakhs in the same quarter last year — a decline of roughly 15%. The company posted a loss before tax of Rs. 148.01 lakhs (vs. a loss of Rs. 117.13 lakhs in Q1 FY25), and a net loss after tax of Rs. 129.04 lakhs, wider than the Rs. 85.70 lakh loss a year ago. For the full FY25, revenue stood at Rs. 1,007.46 lakhs with a full-year net loss of Rs. 464.57 lakhs. The statutory auditor (A.M. Reddy & D.R. Reddy) issued an unqualified limited review report. The board also approved the 34th AGM notice (September 30, 2025) and re-appointments of the Managing Director and two Whole-time Directors for a second three-year term starting October 19, 2025.
Weak operating performance continues with shrinking revenue and widening quarterly losses, which is negative for shareholders. Re-appointments of senior directors and an unchanged auditor suggest management continuity, but the persistent losses raise questions about path to profitability.